Proteasome inhibitor MG132 enhances the sensitivity of human OSCC cells to cisplatin via a ROS/DNA damage/p53 axis

Cis-diamine-dichloroplatinum II (cisplatin, CDDP) is a key chemotherapeutic regimen in the treatment of oral squamous cell carcinoma (OSCC). However, the therapeutic efficacy of cisplatin in OSCC may be hampered by chemoresistance. Therefore, the development of novel combination therapy strategies t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Zheng, Wang, Xiang, Chen, Donglei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133788/
https://www.ncbi.nlm.nih.gov/pubmed/37123203
http://dx.doi.org/10.3892/etm.2023.11924

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133788/
https://www.ncbi.nlm.nih.gov/pubmed/37123203
http://dx.doi.org/10.3892/etm.2023.11924

Ejemplares similares